| Literature DB >> 26971849 |
Ulrich-Frank Pape1, Sebastian Maasberg2, Henning Jann2, René Pschowski2, Sandrine Krüger2, Vikas Prasad3, Timm Denecke4, Bertram Wiedenmann2, Andreas Pascher5.
Abstract
Neuroendocrine neoplasias (NEN) comprise heterogeneous epithelial neoplasms with a large variety of clinical presentations, treatment options and outcomes. Since potentially all NEN bear malignant potential it is important for long-term clinical management and improvement of outcome to decide on successful and oncologically and economically meaningful follow-up strategies. Evidence-based outcome data validating specific follow-up strategies are, however, not available to date and thus outcome data, known prognostic factors and clinical experience guide the decisions on follow-up regimens. The review summarizes general recommendations as well as specific considerations based on tumor entities, clinicopathological tumor characteristics and clinical experience. Follow-up shall serve the patient to improve outcome, benefit from more effective therapies and suffer less from unnecessary and/or toxic therapeutic interventions and finally preserve or gain a good quality of life.Entities:
Keywords: follow-up; grading; neuroendocrine neoplasia; outcome; primary tumor; prognosis; quality of life; staging
Mesh:
Year: 2016 PMID: 26971849 DOI: 10.1016/j.beem.2016.02.001
Source DB: PubMed Journal: Best Pract Res Clin Endocrinol Metab ISSN: 1521-690X Impact factor: 4.690